|
CONSULTATIVE BOARD
Dr. Guillermo Antiñolo (Sevilla, España)
Dra. Teresa Leis (Mexico)
Dr. Mario Palermo (Argentina)
Dr. Juan Trecet (San Sebastian, España)
Dr. Juan Troyano (Santa Cruz de Tenerife, España)
Dr. Adolfo Uribarren (Bilbao, España)
Dr. Javier Valero (Madrid, España)
Dra. Susana Vilaseca (Vic, España)
|
|
COORDINATORS
Dr. J.C. Santiago Blazquez
Dr. D.J. Ramos-Corpas
Dr. M. Gallo Vallejo
|
|
|
TRANSLATORS
PORTUGUESE:
Prof. Dr. Antonio Helio Oliani
Profª Drª Denise Cristina Mós Vaz-Oliani
INSTITUTO DE MEDICINA REPRODUTIVA E FETAL
|
|
SPONSORS

Asociación Española de Medicina Fetal
|
|
FetalTest.com is a Web Page that is sponsored by Sociedad Española Ginecologia y Obstetricia (S.E.G.O.) and by Sociedad IberoAmericana de Diagnóstico y Tratamiento Prenatal (S.I.A.D.T.P.), which seeks to facilitate the use of different strategies for prenatal trisomy screening, with the twofold goal of reducing the rate of invasive techniques needed, and increasing the sensitivity of prenatal diagnosis.
This Web Page includes a program enabling the online performance of the necessary calculations to screen for Trisomy 21 and Trisomy 18 and 13, and to store the results on a data base for later analysis and assessment. This program uses a calculation method based on the uni, bi or multi-variable algorithms of the Gaussian Model of the Logarithm of Multiples of the Median. In addition, this program is designed to provide a printed copy of the screening report, which can be given to the mother immediately, and to carry out a rigorous quality control of the screening operations performed.
As scientific knowledge progresses continually, this program must necessarily be updated on an ongoing basis to incorporate the latest advances. At present, version 2.1 of FetalTest is available; this was designed to enable the use of different screening strategies, both the classical ones (triple, quadruple or quintuple test in the second quarter), and more recent ones (combined first quarter test) and others that are now being proposed (such as the various modes integrating markers, in the first and second quarter). In addition, this new version makes it possible to perform screening for Smith Lemli Opitz syndrome and for Neural Tube Defects if the appropriate markers are used in the second quarter.
The efficiency of screening for chromosome defects depends fundamentally on the quality of the measurements made and on their adequate control. To achieve this overriding goal, the use of FetalTest requires Authorization, both because of the need for training in the echographic assessment of Nuchal Translucency and to confirm the user?s awareness of the scientific fundaments of prenatal screening for chromosome defects. Therefore Authorization for the use of FetalTest is subject to exhaustive, continuous control of the quality of the data submitted by participating doctors.
If you are authorized, please enter your User Name and Password:
|
NUEVA VERSION DE FETALTEST: v 2.1
La base de datos de la versión 1.0 ha sido volcada a la nueva versión, por lo que los usuarios pre-existentes pueden seguir controlando sus datos previos.
Para los usuarios que lo deseen pueden seguir accediendo temporalmente a la antigua versión siguiendo este enlace: FetalTest v 1.0.
Para ambas versiones se mantienen las mismas claves de acceso.
|
|